In case you missed it: Checkpoint Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted approval for UNLOXCYT (cosibelimab-ipdl), a treatment for adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are ineligible for curative surgery or radiation. Read below for insights from James Oliviero, CFA, President and Chief Executive Officer of Checkpoint, on this significant milestone.
Congratulations to the team! Looking forward to hear about the commercial planning, but this major one is in the pocket!
James - Congratulations to you and everyone at Checkpoint!! And thanks for providing patients with a much needed treatment option!!
Congrats!
Congratulations to the whole team!
I help my clients make more money, save more money, and improve user experiences.
3wOutstanding news, and better yet hope for patients who need differentiated treatment options!